174 related articles for article (PubMed ID: 36103953)
21. A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders.
Caillard S; Cellot E; Dantal J; Thaunat O; Provot F; Janbon B; Buchler M; Anglicheau D; Merville P; Lang P; Frimat L; Colosio C; Alamartine E; Kamar N; Heng AE; Durrbach A; Moal V; Rivalan J; Etienne I; Peraldi MN; Moreau A; Moulin B;
Clin J Am Soc Nephrol; 2017 Oct; 12(10):1663-1670. PubMed ID: 28818847
[TBL] [Abstract][Full Text] [Related]
22. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus.
Sindhi R; Webber S; Venkataramanan R; McGhee W; Phillips S; Smith A; Baird C; Iurlano K; Mazariegos G; Cooperstone B; Holt DW; Zeevi A; Fung JJ; Reyes J
Transplantation; 2001 Sep; 72(5):851-5. PubMed ID: 11571449
[TBL] [Abstract][Full Text] [Related]
23. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
Birkeland SA; Andersen HK; Hamilton-Dutoit SJ
Transplantation; 1999 May; 67(9):1209-14. PubMed ID: 10342310
[TBL] [Abstract][Full Text] [Related]
24. Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage.
Crane GM; Powell H; Kostadinov R; Rocafort PT; Rifkin DE; Burger PC; Ambinder RF; Swinnen LJ; Borowitz MJ; Duffield AS
Oncotarget; 2015 Oct; 6(32):33849-66. PubMed ID: 26460822
[TBL] [Abstract][Full Text] [Related]
25. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005.
Chang SH; Russ GR; Chadban SJ; Campbell S; McDonald SP
Nephrology (Carlton); 2008 Apr; 13(2):171-6. PubMed ID: 18275507
[TBL] [Abstract][Full Text] [Related]
26. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
[TBL] [Abstract][Full Text] [Related]
27. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey.
San-Juan R; Manuel O; Hirsch HH; Fernández-Ruiz M; López-Medrano F; Comoli P; Caillard S; Grossi P; Aguado JM; ;
Clin Microbiol Infect; 2015 Jun; 21(6):604.e1-9. PubMed ID: 25686696
[TBL] [Abstract][Full Text] [Related]
28. [Immunosuppression for kidney transplant recipients: current strategies].
Alberú J; Urrea EM
Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
[TBL] [Abstract][Full Text] [Related]
29. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
Grigg SE; Sarri GL; Gow PJ; Yeomans ND
Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
[TBL] [Abstract][Full Text] [Related]
30.
Krueger MB; Bonifacius A; Dragon AC; Santamorena MM; Nashan B; Taubert R; Kalinke U; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
Transpl Int; 2024; 37():12720. PubMed ID: 38655204
[TBL] [Abstract][Full Text] [Related]
31. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
Allen UD; Preiksaitis JK;
Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
[TBL] [Abstract][Full Text] [Related]
32. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
Lindsay J; Yong MK; Greenwood M; Kong DCM; Chen SCA; Rawlinson W; Slavin M
Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors.
Kühne JF; Neudörfl C; Beushausen K; Keil J; Malysheva S; Wandrer F; Haller H; Messerle M; Blume C; Neuenhahn M; Schlott F; Hammerschmidt W; Zeidler R; Falk CS
Transpl Immunol; 2020 Aug; 61():101291. PubMed ID: 32330566
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus DNA load and seroconversion in pediatric renal transplantation with tacrolimus immunosuppression.
Suzuki T; Ikezumi Y; Okubo S; Uchiyama M; Takahashi K; Shiraga H; Hattori M
Pediatr Transplant; 2007 Nov; 11(7):749-54. PubMed ID: 17910652
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders.
Boratyńska M; Smolska D
Transpl Int; 2008 Jun; 21(6):605-8. PubMed ID: 18282244
[No Abstract] [Full Text] [Related]
38. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.
Majewski M; Korecka M; Kossev P; Li S; Goldman J; Moore J; Silberstein LE; Nowell PC; Schuler W; Shaw LM; Wasik MA
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4285-90. PubMed ID: 10759564
[TBL] [Abstract][Full Text] [Related]
39. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
[TBL] [Abstract][Full Text] [Related]
40. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
